Stepped Up Clinical Efforts Targeting Breast Cancer Therapies and Treatments Leading to Opportunistic Options
- Financialnewsmedia.com News Commentary
PALM BEACH, Fla., Aug. 26, 2020 /PRNewswire/ -- Although various market revenue projections may differ in the total dollar figures, the reports in the triple negative breast cancer (TNBC) treatment market all predict a sustainable growth oner the next several years to come. A previous report from Mind Aspire Market Research was trumped by another report from Future Wise Research. The Mind Aspire report estimated the global triple-negative breast cancer treatment market revenue is projected to reach US$727 Million by the end of 2026 and grow at a CAGR of 4.9% during the forecast period, while the Future Wise report projected a higher figure, forecasting a value of over US$ 820 million by 2027 end and register a CAGR of over 4.5% from 2020 to 2027. The Future report said it relied upon the rising advancements in research related to cancer, that have led to new drugs being introduced to diagnose and treat cancer. The entrance of new drugs and treatments are aimed at improving the treatment rate against triple-negative breast cancer. Latest clinical efforts are being targeted towards molecular characterization stage of triple-negative breast cancer across rising remedial targets like androgen receptors, PARP1, and non- receptor & receptor tyrosine kinases. Active biotech and pharma companies in the markets this week include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Orchard Therapeutics (NASDAQ: ORTX), Heat Biologics, Inc. (NASDAQ:HTBX), Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Bristol Myers Squibb (NYSE:BMY).
The report added: "These latest actions are expected to boost the growth of the triple-negative breast cancer treatment market. Development of generics remains a lucrative area for the market. The growing need for effective cancer management and more efficient drugs is expanding the size of the market. The availability of biosimilars in developing regions is proving to be an efficient drug which has resulted in the growth of the market. The rising number of clinical trials for the combined therapies is boosting the growth of the market as well. New drug formulations are currently in the processing stages of different phases of clinical development and this has augured the growth of the market."
Heat Biologics Registered (Old) Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de